Anti-TGF-beta monoclonal antibody GC1008

From Wikipedia, the free encyclopedia

Anti-TGF-beta monoclonal antibody GC1008 is a monoclonal antibody being studied in the treatment of kidney cancer, melanoma, and pulmonary fibrosis. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-TGF-beta monoclonal antibody GC1008 binds to the protein transforming growth factor-beta (TGFß) and may block the growth of cancer cells that make it. Also called GC1008.

[edit] External links

This article includes text from the U.S. National Cancer Institute's public domain Dictionary of Cancer Terms